- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14:18 | Avalyn Pharma to present 4-year AP01 data at EULAR conference | 2 | Investing.com | ||
| 14:06 | Avalyn Pharma Inc.: Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026 | 2 | GlobeNewswire (USA) | ||
| AVALYN PHARMA Aktie jetzt für 0€ handeln | |||||
| 01.05. | Avalyn Pharma: Erfolgreicher Börsengang an der NASDAQ bringt 345 Millionen US-Dollar ein | 3 | Investing.com Deutsch | ||
| 01.05. | Avalyn Pharma closes $345 million IPO on Nasdaq | 2 | Investing.com | ||
| 01.05. | Avalyn Pharma Inc.: Avalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 2 | GlobeNewswire (USA) | ||
| 01.05. | Avalyn Pharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.04. | Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials | 1 | MedCity News | ||
| 30.04. | Lung disease drug developer Avalyn surges on public debut | 1 | Seeking Alpha | ||
| 30.04. | Börsengang von Avalyn Pharma: Hohe Überzeichnung und konzentrierte Zuteilung | 3 | Investing.com Deutsch | ||
| 30.04. | Avalyn seeks $300m from its IPO | 1 | pharmaphorum | ||
| 30.04. | Pulmonary fibrosis biotech Avalyn Pharma prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
| 30.04. | Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs | 1 | FierceBiotech | ||
| 30.04. | Avalyn Pharma prices $300M IPO at $18 per share | 1 | Seeking Alpha | ||
| 30.04. | Avalyn Pharma Prices Upsized $300 Mln IPO At $18 Per Share | 618 | AFX News | WASHINGTON (dpa-AFX) - Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 16.67 million shares at a price... ► Artikel lesen | |
| 30.04. | Avalyn Pharma Inc.: Avalyn Announces Pricing of Upsized Initial Public Offering | 211 | GlobeNewswire (Europe) | BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) ("Avalyn"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm... ► Artikel lesen | |
| 30.04. | Avalyn Pharma prices upsized IPO at $18 per share | 2 | Investing.com | ||
| 29.04. | Pulmonary fibrosis biotech Avalyn Pharma increases shares offered by 41% ahead of $283 million IPO | 4 | Renaissance Capital | ||
| 27.04. | Avalyn Pharma Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 24.04. | Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs | 1 | FierceBiotech | ||
| 23.04. | Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO | 1 | Renaissance Capital |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOVANT | 34,160 | +29,94 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| RELAY THERAPEUTICS | 13,650 | +13,09 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,620 | +2,56 % | Tango Therapeutics Shares Fall 17% | ||
| QIAGEN | 30,095 | +0,62 % | QIAGEN N.V.: QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA | Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases Goal to advance how disease mechanisms... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 80,61 | -0,05 % | Kymera presents KT-621 atopic dermatitis trial data at conferences | ||
| SUMMIT THERAPEUTICS | 17,475 | +10,25 % | H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT) | ||
| PRAXIS PRECISION MEDICINES | 350,56 | +9,34 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 21,010 | +2,64 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,110 | +5,07 % | Recursion Pharmaceuticals (RXRX): 10 Unrivaled Penny Stocks to Buy Now | ||
| NUVALENT | 101,24 | +0,24 % | Nuvalent, Inc.: Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results | NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC
NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review... ► Artikel lesen | |
| ERASCA | 11,600 | +12,40 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| EVOTEC | 5,080 | +3,67 % | KAUFKURSE bei Renk und Desert Gold! SCHOCK bei der Evotec Aktie! | Während der Goldpreis schwächelt, befindet sich die Aktie von Desert Gold in einem sauberen Aufwärtstrend. Und geht es nach Analysten, ist eine Vervielfachung möglich. Denn Desert Gold wird in wenigen... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,570 | +4,22 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results | - Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,540 | +6,85 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update | Reaffirmed FDA alignment on TSHA-102 BLA pathway, including pivotal trial design, endpoints and potential to submit for approval based on REVEAL pivotal trial 6-month interim analysis, following... ► Artikel lesen | |
| ALUMIS | 22,170 | +0,59 % | This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday |
AVALYN PHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,300 (+1,07 %) liegt der Kurs bei 28,410 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AVALYN PHARMA INC finden Sie auf Wallstreet Online.